China’s drug regulator granted conditional approval for Pfizer’s drug Paxlovid on Saturday. Paxlovid is effective against ongoing COVID-19 infections and attenuates its progression. The drug is approved in China for the treatment of adults with mild to moderate illness. Further studies are required to allow for unrestricted approval, the agency said.
Continue reading now
Get 30 days of free access to the Professional Briefing to read these and more quality news every day.
Are you already a guest at the China.Table? Log in now